Status:
COMPLETED
To Evaluate the Efficacy and Safety in Patients With Dyslipidemia and Hypertension
Lead Sponsor:
JW Pharmaceutical
Conditions:
Dyslipidemia
Hypertension
Eligibility:
All Genders
19-100 years
Phase:
PHASE3
Brief Summary
A Multi-center, Randomized, Double-blind, Parallel, phase III Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0101+C2101 in Patients with Dyslipidemia and Hypertension.
Detailed Description
Multicenter, randomized, double-blind, parallel-design, phase III clinical study
Eligibility Criteria
Inclusion
- Patients with hypertension and dyslipidemia
Exclusion
- The subject not meet the specified msBP and LDL-C level
Key Trial Info
Start Date :
November 15 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 8 2022
Estimated Enrollment :
155 Patients enrolled
Trial Details
Trial ID
NCT05331014
Start Date
November 15 2021
End Date
November 8 2022
Last Update
March 15 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Gangdong Sacred Heart Hospital
Seoul, Korea, South Korea, 134-701